Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25156600 | 0.87 | CYP3A4 (0.35) | CYP3A4POLBSMN1; SMN2WEE1PNMT | |
| SCHEMBL20312856 | 0.87 | HTR2C (0.38) | PNMTHTR2CASIC3HTR2BCD44 | |
| SCHEMBL10100734 | 0.84 | — | — | |
| SCHEMBL30590165 | 0.83 | ASIC3 (0.42) | CYP3A4POLBSMN1; SMN2PNMTHTR2C | |
| SCHEMBL714493 | 0.83 | ASIC3 (0.42) | CYP3A4POLBSMN1; SMN2PNMTHTR2C | |
| Hydrochloric Acid SCHEMBL30331765 | 0.82 | ASIC3 (0.41) | CYP3A4POLBSMN1; SMN2HTR2CASIC3 | |
| Hydrochloric Acid SCHEMBL1119771 | 0.82 | ASIC3 (0.41) | CYP3A4POLBSMN1; SMN2HTR2CASIC3 | |
| Hydrochloric Acid SCHEMBL1119948 | 0.82 | ASIC3 (0.41) | CYP3A4POLBSMN1; SMN2HTR2CASIC3 | |
| Hydrochloric Acid SCHEMBL1119945 | 0.82 | ASIC3 (0.41) | CYP3A4POLBSMN1; SMN2HTR2CASIC3 | |
| SCHEMBL29639953 | 0.77 | PNMT (0.41) | CYP3A4POLBSMN1; SMN2PNMTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9181239-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8796259-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | CYP3A4 1922/4885POLB 1112/4885SMN1; SMN2 3193/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | CYP3A4 2462/4885POLB 2006/4885SMN1; SMN2 1143/4885 |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | CYP3A4 2273/4885POLB 4194/4885SMN1; SMN2 3716/4885 |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CYP3A4 1652/4885POLB 1318/4885SMN1; SMN2 4043/4885 |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | CYP3A4 3953/4885POLB 2200/4885SMN1; SMN2 1868/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | CYP3A4 1584/4885POLB 3767/4885SMN1; SMN2 3927/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CYP3A4 3958/4885POLB 2256/4885SMN1; SMN2 1691/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | CYP3A4 761/4885POLB 3049/4885SMN1; SMN2 3550/4885 |
| US-20130090330-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | CYP3A4 2273/4885POLB 4194/4885SMN1; SMN2 3716/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CYP3A4 1652/4885POLB 1318/4885SMN1; SMN2 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.